Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
30397362
DOI
10.5507/bp.2018.064
Knihovny.cz E-zdroje
- Klíčová slova
- daratumumab, multiple myeloma, overall survival, progression free survival, relapsed and refractory,
- MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie MeSH
- mnohočetný myelom farmakoterapie mortalita MeSH
- monoklonální protilátky terapeutické užití MeSH
- přežití bez známek nemoci MeSH
- protinádorové látky terapeutické užití MeSH
- recidiva MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- daratumumab MeSH Prohlížeč
- monoklonální protilátky MeSH
- protinádorové látky MeSH
OBJECTIVE: The treatment of relapsed and refractory multiple myeloma (RRMM) remains challenging. The outcomes in highly pretreated populations are unsatisfactory and there is urgent need for novel and safe therapeutic approaches. Recently, daratumumab has been approved for RRMM with promising results even in monotherapy. The aim of this study was to assess the efficacy of single agent daratumumab outside a clinical trial. PATIENTS AND METHODS: 14 patients with RRMM and significant pretreatment (median 4.5 previous lines) entered a specific healthcare program and received treatment with single agent daratumumab. They were followed for therapeutic response based on IMWG criteria, and incidence of adverse events. The data were collected using the Registry of Monoclonal Gammopathies. RESULTS: The overall response rate was 38.5%. 23.1% of patients reached very good partial response, 15.4% reached partial remission, 15.4% had minimal response, 38.5% had stable disease and 7.7% had progressive disease. The median progression free survival was 4.6 months and median overall survival was not achieved. The toxicities were mostly mild, only infectious complications and hematological toxicity reached grade III. CONCLUSION: We conclude that daratumumab has significant activity in highly pretreated RRMM even as a single agent, with an acceptable toxicity profile and survival impact.
Department of Clinical Hematology University Hospital Hradec Kralove Czech Republic
Department of Haemato Oncology University Hospital Pilzen Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Czech Republic
Department of Internal Medicine University Hospital Praha Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
